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ABSTRACT
25e30% of families fulfilling the criteria for hereditary
diffuse gastric cancer have germline mutations of the
CDH1 (E-cadherin) gene. In light of new data and
advancement of technologies, a multidisciplinary
workshop was convened to discuss genetic testing,
surgery, endoscopy and pathology reporting. The
updated recommendations include broadening of CDH1
testing criteria such that: histological confirmation of
diffuse gastric criteria is only required for one family
member; inclusion of individuals with diffuse gastric
cancer before the age of 40 years without a family
history; and inclusion of individuals and families with
diagnoses of both diffuse gastric cancer (including one
before the age of 50 years) and lobular breast cancer.
Testing is considered appropriate from the age of
consent following counselling and discussion with
a multidisciplinary team. In addition to direct sequencing,
large genomic rearrangements should be sought. Annual
mammography and breast MRI from the age of 35 years
is recommended for women due to the increased risk for
lobular breast cancer. In mutation positive individuals
prophylactic total gastrectomy at a centre of excellence
should be strongly considered. Protocolised endoscopic
surveillance in centres with endoscopists and
pathologists experienced with these patients is
recommended for: those opting not to have gastrectomy,
those with mutations of undetermined significance, and
in those families for whom no germline mutation is yet
identified. The systematic histological study of
prophylactic gastrectomies almost universally shows
pre-invasive lesions including in situ signet ring
carcinoma with pagetoid spread of signet ring cells.
Expert histopathological confirmation of these early
lesions is recommended.
OVERVIEW
Gastric cancer is the fourth most common cause of
cancer worldwide; by 2030 deaths from gastric
cancer globally are predicted to have risen from the
15th to the 10th leading cause of mortality from all
causes.1 The vast majority of gastric cancers are
sporadic, although it has now been established that
1e3% of gastric cancers arise as a result of inherited
gastric cancer predisposition syndromes.2e4
Inherited gastric cancers are more commonly of the
diffuse type or linitis plastica and are generally
referred to as hereditary diffuse gastric cancer
(HDGC). In order for a family to qualify for
a diagnosis of HDGC the following criteria have
been used5 6:
1. Two or more documented cases of diffuse gastric
cancer in ﬁrst or second degree relatives, with at
least one diagnosed before the age of 50, or
2. Three or more cases of documented diffuse
gastric cancer in ﬁrst/second degree relatives,
independent of age of onset.
Over 10 years ago linkage analysis implicated
germline mutations of the tumour suppressor gene
E-cadherin (CDH1) as the genetic cause of HDGC.7
Shortly afterwards it was estimated that about 25%
of families fulﬁlling the clinical criteria for HDGC
would have inactivating CDH1 germline muta-
tions.5 The trigger and molecular mechanism by
which the second allele of E-cadherin is subse-
quently inactivated appears to be diverse and
includes methylation, mutation and loss of
heterozygosity (LOH)8 9 Published data from these
families suggest that the penetrance of CDH1 gene
mutations is high,10 with an estimated risk of>80%
(analysis updated in 2008, unpublished data). In
other words, carriage of the abnormal E-cadherin
gene confers more than an 80% lifetime risk of
developing gastric cancer. The causal germline
mutations accounting for HDGC cases without an
identiﬁed defect in CDH1 are currently unknown.
Increasing awareness of HDGC and the rapid
advances in genetic diagnostic tools, endoscopic
modalities and the increasing use of laparoscopic
surgery led a group of clinical geneticists, gastro-
enterologists, surgeons, oncologists, pathologists
and molecular biologists from nine different coun-
tries to convene a workshop in order to update the
management guidelines for this condition originally
set in 1999 and to propose directions for future
research. The workshop discussions were focused
on four major topics: (1) genetic counselling and
testing; (2) endoscopic surveillance of the stomach
and screening for other cancers; (3) prophylactic
gastrectomy; and (4) pathological specimen
processing and diagnosis.
GENETIC COUNSELLING AND TESTING
Genetic counselling is an essential component
of the evaluation and management of HDGC.
The genetic evaluation should include a careful
three-generation family pedigree, histopathological
conﬁrmation of diffuse gastric cancer diagnoses or
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precursor lesions, a discussion of lifetime risks of diffuse gastric
cancer (updated to >80% in both men and women by age 80)
and lobular breast cancer (updated to 60% in women by age 80),
and current CDH1 mutation detection rates (25e50%).9e11
Informed consent for genetic testing is required. The counselling
process should include not only a formal genetics evaluation
but also the input from a multidisciplinary team (MDT)
comprising those with relevant expertise in gastric surgery,
gastroenterology, pathology, and nutrition. Ideally, the full team
should be engaged in both the pre-genetic testing and post-
genetic testing phases, but MDT involvement is mandatory in
the post-test setting.
Genetic testing should be initiated in an affected proband. The
recommended youngest age at which to offer testing to relatives
at risk is not well established. Rare cases of clinically signiﬁcant
diffuse gastric cancer have been reported in affected families
before the age of 18, but the overall risk of diffuse gastric cancer
before the age of 20 is very low.10 12 It was agreed that consid-
eration of genetic testing can begin at the age of consent (16/
18 years), but that the testing of family members under 18 years
should consider the earliest age of cancer onset in HDGC
families from the local population and the psychological,
emotional, and physical health of the individual and their
family. For example, in New Zealand, CDH1 mutation carriers
have developed gastric cancer in their mid teens; as a conse-
quence, genetic testing begins at 16 years of age, and occasion-
ally 1e2 years before, on a case by case basis.
While the workshop endorsed the clinical deﬁnition of
hereditary diffuse gastric cancer established in 1999, the criteria
for which are stated above,5 they also recommended a broader
set of clinical criteria as indications for genetic testing for CDH1
mutations: namely, relaxation of the restriction for histopath-
ological conﬁrmation of diffuse gastric criteria to one family
member, inclusion of individuals with diffuse gastric cancer
before the age of 40 years without a family history, and inclu-
sion of individuals and families with diagnoses of both diffuse
gastric cancer (including one case below the age of 50 years) and
lobular breast cancer (ﬁgure 1). In addition, in cases where expert
pathologists detect in situ signet ring cells and/or pagetoid
spread of signet ring cells adjacent to diffuse type gastric cancer,
genetic testing should be considered since this is rarely if ever
seen in sporadic cases.13
In previous studies the detection rate of CDH1 mutations was
reported to be 25e50%11 14 15 when the following criteria were
used for inclusion: histologically conﬁrmed diffuse gastric cancer
in three ﬁrst degree family members at any age, or two or more
gastric cancers in ﬁrst degree relatives with at least one
conﬁrmed diffuse gastric cancer diagnosed before age 50.
Importantly, 4% of these mutation positive families exhibited
large germline deletions of CDH1 that were not detectable by
conventional DNA sequencing.16 Genetic testing on blood for
germline mutations should be performed in Clinical Laboratory
Improvement Amendments (CLIA) approved molecular
diagnostic laboratories or research laboratories with expertise in
CDH1 gene analysis. Analysis of large genomic deletions with
multiplex ligation dependent probe ampliﬁcation (MLPA) or
alternative methods (array comparative genomic hybridisation
(CGH)) is recommended in cases where DNA sequencing is
unrevealing.16 When blood is not available consideration should
be given to testing DNA from parafﬁn, although any results
Figure 1 Algorithm for management
starting from clinical criteria, genetic
testing, role of endoscopy and
gastrectomy. EGD,
oesophagogastroduodenoscopy; MLPA,
multiplex ligation dependent probe
amplification.
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from this material need to be treated cautiously and rigorously
conﬁrmed (ﬁgure 2).
By genetic criteria, any family with a germline CDH1
mutation would comprise an HDGC kindred. It is critical that
families who meet clinical criteria for HDGC, but do not carry
an identiﬁable CDH1 mutation or who carry a CDH1 variant
that does not result in a truncated protein, are registered for
clinical research studies. Whenever possible, it is important to
deﬁne the pathogenicity of CDH1 variants including missense
alterations, and the following terminology should be used
to classify these variants: silent polymorphism, variant of
uncertain signiﬁcance, likely deleterious variant.17 Assessment
of pathogenicity of such missense mutations relies on in vitro
assays of E-cadherin dependent cellular aggregation and invasion
or in silico analyses that predict alterations in E-cadherin protein
function based upon conserved evolutionary motifs.18e20
Furthermore, it is likely that there are additional genetic loci
independent of CDH1 that confer an increased risk of diffuse
gastric cancer, and careful identiﬁcation and characterisation of
such diffuse gastric cancer families without known pathogenic
CDH1 mutations is a prerequisite to deﬁning these loci.
Endoscopic assessment for gastric cancer in individuals with
a germline CDH1 mutation is described in detail under ‘Endo-
scopic surveillance’. The management for those with clinical
features suggestive of HDGC but without a germline CDH1
mutation is not straightforward. We would recommend that
intensive endoscopic surveillance should also be offered to
families who fulﬁl the revised criteria as set out in ﬁgure 1.
With the increasing evidence for a risk of lobular breast cancer
for females who carry pathogenic CDH1 mutations, it was
recommended that enhanced breast cancer screening should be
strongly considered. There are currently insufﬁcient data on the
role and outcome of breast cancer screening in this population,
but the high lifetime risk of breast cancer, particularly the
lobular subtype, and the precedents established in other hered-
itary breast cancer syndromes establish a rationale. Referral to
a high risk breast clinic is recommended. For those who choose
to undergo screening, we recommend monthly breast self
examinations starting at age 35, annual mammogram and breast
MRI, and a biannual clinical breast examination. The age of 35 is
a pragmatic choice but accurate age related penetrance for breast
cancer data is needed in order to conﬁrm the age at which
screening should be commenced. In the meantime, in view of
the current lack of evidence, breast screening should be carried
out in the context of a research protocol as this may permit the
formulation of evidence based guidelines in the future. Prophy-
lactic mastectomy cannot be uniformly recommended, but it
may be a reasonable option for some women. There are insuf-
ﬁcient data to recommend chemoprevention with tamoxifen.
There is also emerging evidence for an increased risk of colon
cancer in HDGC families, and these colon cancers can display
signet ring cell features (D Huntsman, P Pharoah, personal
communications 2009). In CDH1 families in which colon cancer
is reported, information should be collected concerning the age
at diagnosis, whether the affected member(s) are ﬁrst or second
degree relatives, and whether the pathology was mucinous or
showed signet ring cells. Depending on these factors, enhanced
screening should be considered with colonoscopy beginning at
age 40 or 10 years younger than the youngest diagnosis of colon
cancer, whichever is younger, and repeated at intervals of
3e5 years. It is imperative that data on colonoscopic screening
in these individuals are collated so that these guidelines can be
evidenced based in the future.
ENDOSCOPIC SCREENING AND SURVEILLANCE
To clarify the terminology, individuals having endoscopy who do
not have a CDH1 mutation are having screening, whereas
mutation positive individuals are undergoing surveillance. The
consensus reached at the workshop was that individuals who
tested positive for a CDH1 mutation should be advised to
consider prophylactic gastrectomy regardless of any endoscopic
ﬁndings. However, the timing of this operation may vary
according to the preferences and age as well as the physical and
psychological ﬁtness of the individual. In patients going forward
for gastrectomy a baseline endoscopy should be performed
before surgery to look for macroscopic tumour and in order to
inform the data on endoscopic detection of microscopic lesions.
The information on microscopic disease foci is useful to compare
with ﬁndings in the surgical resection specimen and hence to
inform the data on the likelihood of endoscopic detection of
microscopic lesions. For individuals in whom gastrectomy is not
currently being pursued (eg, through patient choice), annual
endoscopy should be offered in order to ensure that there is no
evidence of clinically signiﬁcant lesions and for research purposes
(assuming ethical approval) in order to help understand the
natural history of early lesions. Similarly, if the CDH1 positive
individual declines gastrectomy then endoscopic surveillance
should be offered under a research protocol. In these individuals
surveillance can have the advantage of helping them to come to
a decision about the need for gastrectomy, since when micro-
scopic foci of signet ring cells are detected this can help the
individual confront their risks from this mutation. For those
individuals with mutations of undetermined signiﬁcance (eg,
missense), or in those in whom no mutation can be identiﬁed in
the index case, then endoscopy has a useful role to play in
guiding clinical decision making. Speciﬁcally, any malignant
lesions detected endoscopically would prompt a referral for
gastrectomy. However, all patients should be counselled that in
view of the very focal nature of these endoscopically invisible
lesions it is quite possible that they will not be detected by
random biopsies (ﬁgure 1).
ENDOSCOPY PROTOCOL
Individuals should be offered an annual endoscopy that should
ideally be performed in a centre with a special interest in, and
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Figure 2 Germline deletions in CDH1. The CDH1 and CDH3 genes are shown in grey with the exons for CDH1 indicated. The red areas indicate five
deletions detected by multiplex ligation dependent probe amplification.
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experience with, this condition. The endoscopy should be
performed using a white light high deﬁnition endoscope in
a dedicated session with at least 30 min allocated to allow for
a careful inspection of the mucosa on inﬂation and deﬂation,
and to allow time for multiple biopsies to be taken. Use of
mucolytics such as acetylcysteine may be helpful to obtain
good views.
Although there does not appear to be an association between
Helicobacter pylori infection and HDGC, it is important to test for
H pylori to document the prevalence of infection in mutation
carriers. Furthermore, since H pylori is a World Health Organi-
zation class 1 carcinogen it is agreed that when individuals are
infected it should be eradicated.
Due to the tiny microscopic foci of signet ring cells multiple
biopsies are required to maximise the likelihood of diagnosing
them.21 Targeted biopsying of the bodyeantral transitional zone
of the stomach during endoscopic surveillance has been suggested
to increase the diagnostic yield on the basis that in New Zealand
Maori families, a predilection was observed for early invasive
carcinomas to occur in this area of the stomach.12 22 In North
American and European families, early invasive carcinoma was
identiﬁed from the cardia to pre-pyloric region, without evidence
of antral clustering.21 23e26 In a case series reported by Rogers
et al,27 70% of the total foci were localised in the proximal third of
the stomach. In a series from the UK21 the highest number of foci
were again observed in the fundus (44.7%) followed by the body
(40.2%). Reasons for the different anatomical localisation of the
cancer foci in the aforementioned studies remain to be clariﬁed,
but may include environmental factors or differences in the
molecular pathogenesis. Therefore it is recommended that any
endoscopically visible lesions are targeted and that in addition
random sampling of six biopsies is taken for each of the following
anatomical zones: antrum, transitional zone, body, fundus,
cardia. In all a minimum of 30 biopsies are recommended and
a suggested protocol is given in supplementary ﬁgure 1.
Chromoendoscopy was initially trialled with Congo red and
methylene blue28; however, concerns over the toxicity of Congo
red mean that this stain is no longer recommended. Other
chromoendoscopic techniques are currently not recommended
except in the research setting. Endoscopic technologies are
advancing rapidly and the use of trimodal imaging, confocal
endomicroscopy and molecular imaging techniques need to be
explored (eg, Dunbar and Canto, 200929).
In order to maximise the yield from endoscopy, specialist
histopathology reporting is essential and the guidelines outlined
in the pathology section below should be followed.
PROPHYLACTIC GASTRECTOMY
Indications for and timing of surgery
As discussed above, since the penetrance of HDGC is >80%, and
since endoscopic surveillance and analysis of gastrectomy spec-
imens suggests that microscopic foci of signet ring cells are
almost universally present in mutation carriers (see section
entitled Pathology: Classiﬁcation of microscopic foci and deter-
mination of signiﬁcance), surgery should be strongly considered
whenever an at risk family member is found to have a CDH1
mutation as discussed above. However, the timing of the
gastrectomy is debatable. The evidence increasingly suggests
that there is likely to be a dormant period in which the signet
ring cell adenocarcinoma does not spread or progress since they
have a low proliferative index.8 This may explain why so many
individuals are found to have T-1 N-0 stage tumours after
prophylactic gastrectomy.30 However, with our current lack of
knowledge of the behaviour of mucosal signet ring cancer cells,
it is recommended that if they are detected on endoscopic
biopsies the patient should be advised to undergo a total
gastrectomy regardless of age, although it is rare that endoscopy
would be recommended before 16 years. CDH1 mutation posi-
tive patients with normal gastric biopsies should be advised to
undergo gastrectomy once the genetic testing results are known
and once individuals are older than 20 years.12 Patients under the
age of 40 who develop symptomatic invasive diffuse gastric
carcinoma have a poor prognosis with as few as 10% having
early and curable disease.31 As our understanding of the natural
history of mucosal signet ring cancer in HDGC improves it may
be possible to safely leave some patients until they are older, but
until that time it is safer to recommend surgery early in adult
life. This has implications for the long term follow-up of
prophylactic gastrectomy patients, especially women who are
more at risk of iron deﬁciency anaemia and osteoporosis than
men, and re-enforces the need for multidisciplinary teams to care
for these patients.
Prophylactic gastrectomy is clearly a signiﬁcant undertaking.
The decision as to if and when to proceed will therefore be
inﬂuenced by the psychological and physical ﬁtness of the
individual and their occupation and other family commitments.
Therefore, a multidisciplinary approach to preoperative coun-
selling involving a gastroenterologist, surgeon, dietician, genetic
counsellor and specialist nurse is absolutely necessary. This team
should work in a high volume cancer centre with low peri-
operative mortality rates,32 (<1% for ﬁt patients undergoing
total gastrectomy33). There are now reports to show that
pregnancy can be carried to full term following a prophylactic
gastrectomy (manuscript submitted) and individuals are able to
return to full time work including manual workers. Despite this,
the physiological, metabolic and emotional impact of removing
a young adults stomach should not be underestimated.
Operation details
The requisite operation is a total gastrectomy with Roux-en-Y
reconstruction, ensuring that the jejuno-jejunal anastomosis is
at least 50 cm distal to the oesophago-gastric anastomosis to
reduce the risk of biliary reﬂux. The proximal resection line must
be across the distal oesophagus to ensure that no gastric cardia
mucosa is left behind. There is no need for a radical lymph node
dissection in the prophylactic setting since mucosal adenocar-
cinoma without submucosal invasion has a very low risk indeed
of lymph node metastases.34 In view of this, a vagal sparing
resection is possible and there are good theoretical reasons why
this might give an improved quality of life for patients compared
to those undergoing a truncal vagotomy as a byproduct of their
gastrectomy.35 36 Studies are needed to assess the beneﬁts of this
strategy and this group of patients provide a unique population
in which to study various aspects of surgical reconstruction such
as the provision of a pouch. At the current time, although
preliminary studies from Germany and Japan suggest that
a pouch may afford an improved quality of life,37 this requires
further study and the surgeon should continue to do what he or
she is most familiar with. This applies also to whether the
preferred surgical approach is open or laparoscopic. Some teams
have made good progress at safely introducing a minimally
invasive approach to gastric cancer surgery,38 39 but any surgeon
proposing to do a prophylactic gastrectomy laparoscopically
must be able to reassure the patient with audited data that this
is without additional risk. These operations are not suitable to
be done during a surgeons ‘laparoscopic learning curve’. It may
also be very helpful for patients to have a chance to talk to
other individuals who have been through the same operation to
J Med Genet 2010;47:436e444. doi:10.1136/jmg.2009.074237 439
Original article
 group.bmj.com on November 9, 2012 - Published by jmg.bmj.comDownloaded from 
help them make an informed decision and they know what
to expect.
The major issues that worry patients are related to the
morbidity and mortality of the gastric cancer compared to that
of total gastrectomy. The short term and long term morbidity
and mortality of total gastrectomy in these patients does need
to be carefully audited. For example, although a prophylactic
gastrectomy may improve quality of life as a result of a reduc-
tion of the anxiety about stomach cancer, it may worsen
because of the side effects associated with the procedure.
Following a prophylactic gastrectomy patients have to eat
little and often and require support from a dietician. Eating
too much too quickly will cause abdominal pain. Dumping
syndrome can be troublesome and causes a range of symptoms
including pain, nausea, tiredness after eating and diarrhoea.
Other problems may include: lactose intolerance, fat malab-
sorption and steatorrhoea, bacterial overgrowth, and post-
prandial fullness.40 41 Each patient is different after their
surgery and it is impossible to predict how affected they will
be, but all of them will lose weight and require lifelong
vitamin B12injections and close monitoring for conditions such
as anaemia and trace element deﬁciencies. For most patients,
any negative consequences of surgery slowly improve over
the ﬁrst year. Physical function normally returns to normal
by 6 months.
The severity and longevity of complications in previously ﬁt
young individuals following gastrectomy has not been evaluated
and this is an area that requires further research. A central
registry of families and patients treated surgically would be very
helpful to collect data prospectively on the physical and
psychological effects of surgery and improve the care given to
patients in the future. One such registry is currently coordinated
in Cambridge, UK.
PATHOLOGY: CLASSIFICATION OF MICROSCOPIC FOCI AND
DETERMINATION OF SIGNIFICANCE
Currently, there is information available from 96 total gastrec-
tomies in the setting of HDGC, corresponding to published
reports.12 13 21e28 38 42e47 and unpublished observations. These
96 gastrectomies encompass two groups: (1) 73 correspond to
real prophylactic gastrectomies (those performed in CDH1
mutation carriers who had negative biopsies before surgery); (2)
the remaining 23 correspond to total gastrectomies performed in
patients in whom early invasive cancer had been identiﬁed in
preoperative endoscopic biopsies. In the former (real prophy-
lactic gastrectomies), 42 were studied under a research protocol
and early invasive signet ring cell carcinoma was identiﬁed in 39
cases (93%). In two out of the three cases in which early invasive
carcinoma were not identiﬁed, tiny foci of in situ signet ring cell
carcinoma were observed (unpublished observations). In the 31
prophylactic gastrectomies whose study was not performed
under a research protocol, early invasive signet ring cell carci-
noma was identiﬁed in 25 cases (81%). Concerning the total
gastrectomies performed after the preoperative identiﬁcation of
early invasive cancer, all specimens exhibited intramucosal
signet ring cell carcinoma (one or more foci).
The need for a systematic study of these prophylactic speci-
mens is highlighted by the case reported by Gaya et al in which
histopathology was initially reported to be negative,48 and
which was later submitted to a detailed analysis according to
a research protocol. This research analysis led to the identiﬁca-
tion of four foci positive for early invasive carcinoma.49 Similar
ﬁndings had been previously reported by Lewis et al.25
Taken together these systematic studies of prophylactic
gastrectomies have led to the proposal of a model for the
development of diffuse gastric cancer in germline CDH1 dele-
terious mutations carriers which encompasses, as pre-invasive
lesions, in situ signet ring carcinoma with pagetoid spread of
signet ring cells. The discrepancy between the numerous T1a
carcinoma foci and the low number of in situ carcinoma lesions
suggests that invasion of the lamina propria by signet ring cells
may occur without a morphologically detectable in situ carci-
noma.23 50
Special attention should be paid to the two precursor lesions
of early invasive signet ring cell carcinoma: (1) in situ signet ring
cell carcinoma, corresponding to the presence of signet ring cells
within the basal membrane, generally with hyperchromatic and
depolarised nuclei; (2) pagetoid spread of signet ring cells below
the preserved epithelium of glands and foveolae (ﬁgure 3).
Criteria for the identiﬁcation of these lesions should be strictly
followed in order to diminish the risk of over diagnosing non-
speciﬁc changes and distinguishing from lesions that mimic
signet ring cells.51e53 Therefore, conﬁrmation of these lesions by
an independent histopathologist with experience in this area is
strongly recommended.
Background changes in the gastric mucosa of prophylactic
gastrectomy specimens encompass mild chronic gastritis, some-
times displaying the features of lymphocytic gastritis. Occa-
sionally, an inﬂammatory granulomatous reaction is observed at
the periphery of some collapsing glands. Foveolar hyperplasia
and tufting of surface epithelium, focally with globoid change, is
also a frequent ﬁnding and, in some areas, vacuolisation of
surface epithelium is very striking14 23 50 (ﬁgure 4).
Additionally, erosions and cysts may be found in non-
neoplastic mucosa. In most prophylactic gastrectomies reported
so far, intestinal metaplasia and H pylori infection are absent
(families from North America and Europe). The exceptions are
two cases from New Zealand in which H pylori infection was
identiﬁed before surgery (several months or years) and
a gastrectomy performed in a Portuguese patient (unpublished).
An unsolved issue is the distribution of early lesions of HDGC in
the stomach, as discussed above. Therefore it is essential that the
location of biopsies and the positive regions within gastrectomy
specimens are speciﬁcally reported. Additionally, a critical
question that remains unanswered is how long early lesions of
HDGC can remain indolent until there is emergence of clinical
disease that may be rapidly progressive and lethal. Continuing
collection of data is essential to help answer these ques-
tionsdfor example, in the rare individuals who opt for endo-
scopic surveillance until such time as invasive carcinoma is
documented, as discussed above.
REPORTING OF GASTRECTOMY SPECIMENS
Macroscopic observation and sampling of prophylactic gastrec-
tomies should follow speciﬁc protocols. Fresh gastrectomy speci-
mens should be opened along the greater curve (after painting
the margins, dissection of the omentum and retrieval of lymph
nodes) and pinned onto a cork board. A life size specimen photo
should be used as a template to identify the exact location of the
tissue blocks (a schematic map/diagram can be used for that
purpose) (ﬁgure 5). The possibility of collecting and snap freezing
fresh tissue samples from any macroscopic lesion and normal
looking mucosa (lesser and greater curvatures, anterior and
posterior walls of the stomach) for research purposes should be
considered. Overnight ﬁxation in buffered formalin is recom-
mended before sampling for routine histopathology, including
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any macroscopically abnormal areas including pale lesions.
Sections of the margins should be taken (and labelled) and the
remainder of the stomach should be sectioned completely (each
section 2 cm30.3 cm, full thickness) and blocked (parafﬁn
embedded). This usually results in between 100e300 blocks per
stomach. The precise location of each section should be marked
on the map of the stomach. In case gross lesions are found,
these should be precisely localised within the map.
The histological examination should be made using a check-
list focusing on the following issues (see supplementary ﬁgure
2): (1) features of invasive (intramucosal) carcinoma(s), such as
anatomical site (cardia, fundus, body, transitional zone,
antrum), location (greater curvature, lesser curvature, anterior
wall, posterior wall, circumferential), histological type (WHO,
Laurén’s54 and Carneiro’s55 classiﬁcations), lymphatic, venous
and neural invasion (present or absent), precursor lesions such
as in situ carcinoma and pagetoid spread (present or absent),
status of surgical margins, stromal reaction (lymphocytic
inﬁltrates, eosinophilia, desmoplasia and granulomatous reac-
tion); (2) general features of non-neoplastic mucosa (chronic
inﬂammation, activity, H pylori microorganisms, intraepithelial
lymphocytes, intestinal metaplasia, dysplasia); (3) speciﬁc
features of non-neoplastic mucosa (hyperplastic changes,
tufting of surface epithelium, vacuolisation of surface/foveolar
epithelium, ulcers, erosions, granulomas, cysts). In case the
ﬁnal report is presented in the format of a checklist, a summary
should be presented at the end.
In case of restricted time available due to the pathologist’s
workload and lab resourcing, and sometimes requests from the
patients for return of gross specimens, it is not possible to
perform a full embedding of the stomach on a routine basis. In
such cases the minimum examination of a macroscopically
normal gastrectomy should include:
1. Proximal and distal margins to conﬁrm all of the gastric
mucosa has been resected.
2. All lymph nodes should be sampled as per a usual gastrec-
tomy.
3. Photograph.
4. Mapped sampling from all zones; antrum, transitional zone
(angularis incisura), body and fundus.
5. If no foci of carcinoma are found, then to go back to the
specimen and take more blocks. Step4 repeated as time,
workload and resourcing allow.
The report should follow the checklist in supplementary
ﬁgure 2. In the event of not ﬁnding foci of signet ring cell
carcinoma, the gastrectomy should not be reported as negative
for carcinoma, but as ‘no carcinoma found in xx% of mucosa
examined’.
USE OF IMMUNOSTAINING AND HISTOCHEMICAL STAINS
Diffuse or signet ring cell carcinomas are easily detected on
Haematoxylin and eosin (H&E) sections. The use of histo-
chemical stains for neutral mucins, such as periodic acid-Schiff
(PAS) and diastase digestion, may be useful for the detection or
conﬁrmation of tiny intramucosal carcinomas in which the
neoplastic cells are dispersed among preserved foveolae and
glands. E-cadherin immunoexpression has been shown to be
reduced or absent in early invasive gastric carcinomas,
contrasting with the normal membranous E-cadherin expres-
sion in adjacent non-neoplastic mucosa, in keeping with
a clonal origin of the cancer foci. In pagetoid spread lesions and
in situ carcinomas E-cadherin immunoexpression was also
shown to be reduced or absent.23 However, one should be
aware that E-cadherin expression is not always reduced or
absent, depending on the mutation localisation and speciﬁc
mechanisms of inactivation of the wild type allele.
CENTRES OF EXCELLENCE FOR PATHOLOGICAL DIAGNOSIS
Experience in the observation of prophylactic gastrectomies for
HDGC is quite limited in most pathology departments due to
the rarity of these surgical specimens. Additionally, the routine
workload of most centres is incompatible with the detailed
observation of hundreds of sections as those obtained after total
Figure 3 (A) In situ signet ring cell
carcinoma: gland with intact basement
membrane lined by signet ring cells,
with hyperchromatic and depolarised
nuclei. (B) Pagetoid spread of signet
ring cells below the preserved
epithelium of one gland (arrow heads).
(C) Focus of invasive intramucosal
carcinoma T1a, constituted by signet
ring cells (arrows), in the lamina propria.
Figure 4 (A) Foveolar hyperplasia
(between arrows); in comparison to
normal epithelium (below) cells are
globoid (rounded with abundant
cytoplasm). (B) Vacuolisation of the
cytoplasm of superficial and foveolar
cells. (C) Granulomatous reaction at the
periphery of a disrupted gland.
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blocking of those stomachs according to the recommendations
as described above.
In order to increase the experience of pathologists and the
accuracy of the diagnosis, namely of precursor lesions of HDGC,
it would be useful to build a virtual bank of the different types
of lesions observed in the setting of HDGC. Furthermore, the
workshop agreed that the use of scanned slides to be submitted
for evaluation by experienced pathologists in the ﬁeld should be
seriously considered.
To account for the thorough observation of all prophylactic
gastrectomies performed worldwide, a few centres should
be identiﬁed in different geographic regions (Australia/
New Zealand, Canada/USA/Europe) to which material from
prophylactic gastrectomies (whole stomach, parafﬁn blocks,
glass slides and/or virtual slides) should be sent whenever
necessary. These centres could also hold a collection of gastrec-
tomy specimens obtained from individuals with HDGC, since
these are a valuable learning resource.
QUESTIONS ARISING ON MOLECULAR PATHOGENESIS AND
NEED OF RESEARCH
The diminished or absent E-cadherin immunoreactivity observed
in HDGC and its precursor lesions is consistent with bi-allelic
dysfunction of the CDH1 gene. Both alterations (ﬁrst hit,
corresponding to germline mutation in this model, and second
hit by a somatic mechanism for gene inactivation) are expected
to lead to inactivation of CDH1 below a critical threshold which
determines initiation of the neoplastic process.56 57
In the setting of HDGC, a few tumours have been analysed
for second hit inactivation mechanisms. Although somatic
mutations of CDH1 do occur,8 58 promoter hypermethylation
appears to be the most frequent second hit mechanism.8 59 60
Recently, it was shown that the second hit in CDH1 may be
different in primary tumours and metastases, epigenetic changes
(promoter hypermethylation) being more frequent in HDGC
primary tumours and LOH in metastases.9 A thorough analysis
of the mechanisms responsible for the second hit inactivation of
CDH1 in the very early lesions of HDGC is necessary to deﬁne
strategies for chemoprevention.
Alterations in other tumour suppressor genes and oncogenes
are expected to play a role in the pathophysiology of HDGC,
although this issue has rarely been explored in the literature.
Humar et al61 have described that diffuse gastric cancer initiation
seems to occur at the proliferative zone of the gastric epithelium
and correlates with absent or reduced expression of junctional
proteins. Moreover, these authors suggest that progression is
associated with poor differentiation, increased proliferation,
activation of the c-Src system, and epithelialemesenchymal
transition. It remains to be seen if c-Src kinase activation marks
the development of early diffuse gastric cancer. Identiﬁcation of
the molecular mechanisms underlying disease progression is
mandatory to explain why some early intramucosal carcinomas
remain indolent for undeﬁned periods of time, while others
progress to higher stage, clinically signiﬁcant gastric cancer.
In summary, everyone at the workshop was in agreement that
there should be a group of centres caring for these patients
throughout the world and we should have a system to collate
data centrally using website resources, for example. For a rare
condition with such profound implications for the families
affected, it is essential that clinical experiences and research
progress are combined in order to beneﬁt patient management.
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Table 1 Tumour features of patients in the TP53 cohort
Patient Age at onset ER PR HER IHC (FISH) Grade TP53 mutation Effect
1 35 + + 3+ 3 c.672+1G/T Truncating
2 26   2+ (amplified) 3 c.112C/T, (p.Q38X) Truncating
3 24 + + 3+ 3 c.724T/C (p.C242R)* Missense
4 24   3+ 3 c.743G/A, (p.R248Q) Missense
4 (C) 31   3+ 3 As above
5 28 + + 3+ 3 c.659A/G (p.Y220C)y Missense
5 (C) 28 + + 2+ (normal range) 3 As above
6 28 +  3+ 3 c.625A/T (p.R209X) Truncating
7 29  + 3+ 3 c.919+1G/A Truncating
8 24 + + 3+ 3 c.586C/T (p.R196X) Truncating
8 (C) 27 +   2 As above
9 22 + + 3+ 3 c.437G/A (p.W146X) Truncating
*Reported as somatic mutation 13 times and germline once, deleterious (http://www-p53.iarc.fr/MutationValidation.asp).
yReported in 340 tumours and as causative mutation in 6 LFS families, deleterious (http://www-p53.iarc.fr/MutationValidation.asp).
C, Contralateral tumour; ER, Oestrogen Receptor; PR, Progesterone Receptor; HER2, Human Epidermal Growth Factor Receptor 2;
IHC, Immunohistochemistry; FISH, Fluorescent In-Situ Hybridisation.
J Med Genet 2011:48:216. doi:10.1136/jmg.2010.078113corr1
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paper and should read Van Grieken NC.
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